USE OF LEFLUNOMIDE IN RHEUMATOID ARTHRITIS: CLINICAL ASPECTS
- Authors: Kraeva V.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 23, No 5 (2012)
- Pages: 36-38
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115449
- ID: 115449
Cite item
Open Access
Access granted
Abstract
Leflunomide (LEF; Arava) that has anti-proliferative and anti-inflammatory effects is a disease-modifying antirheumatic drug to treat rheumatoid arthritis (RA). Due to its efficacy and safety, LEF may be used as a first-line agent in patients intolerant to methotrexate and in those with early RA.
Full Text
About the authors
V. Kraeva
I.M. Sechenov First Moscow State Medical University
Email: valentinakraeva@yandex.ru
Candidate of Medical Sciences
References
- Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит / Ревматология. Национальное руководство. - Под ред. Е.Л. Насонова, В.А. Насоновой. - М.: ГЭОТАР-Медиа. - 2008; с. 290-331.
- Breedveld F., Dayer J.-M. Leflunomide: mode of action in the treatment of rheumatoid arthritis // Ann. Rheum. Dis. - 2000; 59: 841-9.
- Fairbanks L., Bofil M., Ruckemann K. et al. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans // J. Biol. Chem. - 1995; 270: 29682-91.
- Burger D., Begue-Pastor N., Benavent S. et al. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E2, matrix proteinase 1 and interleukin 6 in human fibroblast-like synoviacytes // Rheumatology (Oxford). - 2003; 42: 89-96.
- Elkayam O., Yaron I., Shirazi I. et al. Active leflunomide metabolite inhibits interleukin 1 ß, tumor necrosis factor а, nitric oxide and metalloproteinase-3 production in activated human synovial tissue cultures // Ann. Rheum. Dis. - 2003; 62: 440-3.
- Palmer G., Burger D., Mezin F. et al. The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes // Arthritis. Res. Ther. - 2004; 6: 181-9.
- Dougados M., Emery P., Lemmel E. et al. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? // Ann. Rheum. Dis. - 2005; 64: 44-51.
- Poor G., Strand V. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomised trial // Rheumatology. - 2004; 43: 744-9.
- Scott D., Strand V. The effects of diseased-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical database // Rheumatology. - 2002; 41: 899-909.
- Osiri M., Shea B., Robinson V. et al. Leflunomide for treating rheumatoid arthritis / Cochrane Database Syst. Rev. - 2003; (1): CD002047.
- Kellner H., Bornholdt K., Hein G. Leflunomide in the treatment of patients with rheumatoid arthritis - results of prospective non-interventional study // Clin. Rheumatol. - 2010; 29: 913-20.
- Kalden J., Antoni C., Alvaro-Gracia J. et al. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis // J. Rheumatol. - 2005; 32: 1620-31.
- Maddison P., Kiely P., Kirkham B. et al. Leflunomide in rheumatoid arthritis: recommendation through a process of consensus // Rheumatology. - 2005; 44: 280-6.
- Kullich W., Mur E., Aglas F. et al. Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomericmatrix protein in patients with rheumatoid arthritis // Clin. Exp. Rheumatol. - 2006; 24: 155-60.
- Targonska-Stepniak B., Dryglewska M., Majdan M. Influence of long-term leflunomide treatment on serum amyloid concentration in rheumatoid arthritis patients // Pharmacological Reports. - 2010; 62: 719-25.
- Smolen J., Landewe R., Breedveld F. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseased-modifying antirheumatic drugs // Ann. Rheum. Dis. - 2010; 69: 964-75.
Supplementary files
